Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease
Jennifer A. Zimmer(Eli Lilly (United States)), John R. Sims(Eli Lilly (United States)), Stephen Salloway(Providence College), Chakib Battioui(Eli Lilly (United States)), Staci E. Engle(Eli Lilly (United States)), Dawn A. Brooks(Eli Lilly (United States)), Diana Otero Svaldi(Eli Lilly (United States)), Alessandro Biffi(Eli Lilly (United States)), Emel Serap Monkul Nery(Eli Lilly (United States)), Steven M. Greenberg(Harvard University), JonDavid Sparks(Eli Lilly (United States)), Steve Lauzon(Eli Lilly (United States)), Mark A. Mintun(Washington University in St. Louis), Hong Wang(Qingdao University), Ming Lu(Chinese Academy of Medical Sciences & Peking Union Medical College), Scott W. Andersen(Eli Lilly (United States)), Cynthia Evans(Eli Lilly (United States)), Rashna Khanna(Eli Lilly (United States)), Paul Ardayfio(Eli Lilly (United States)), Reisa A. Sperling(Harvard University)
Cited by 128
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k